{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T15:24:39Z","timestamp":1792250679075,"version":"4.4.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,5,24]],"date-time":"2025-05-24T00:00:00Z","timestamp":1748044800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,24]],"date-time":"2025-05-24T00:00:00Z","timestamp":1748044800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Interv and Ther"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Lower extremity peripheral arterial disease is usually a consequence of advanced atherosclerosis, leading to high mortality and morbidity. Although clinical characteristics and outcomes may differ among patients having peripheral disease in different arterial territories, contemporary data are scarce. From January 2019 to December 2022, this multicenter registry study included 712 patients undergoing endovascular treatment (EVT) for either aorto-iliac (AI) or femoropopliteal (FP) lesions. Patient characteristics and outcomes were compared between AI-EVT and FP-EVT groups. Clinical endpoints included major adverse cardiovascular events, major adverse limb events (MALE), and all-cause mortality, stratified by chronic limb-threatening ischemia (CLTI). Of the 712 patients, 217 (30.5%) and 495 (69.5%) underwent AI-EVT or FP-EVT. Patients undergoing AI-EVT were more likely to be men and current smokers, while diabetes was more frequent in the FP-EVT group. The prevalence of CLTI was significantly higher in the FP-EVT group. In the entire study population, the FP-EVT rather than the AI-EVT group had a significantly higher rate of MALE and mortality, but the incidence of major adverse cardiovascular events was similar between the two groups. When focusing only on patients without CLTI, the mortality risk was similar, while the MALE risk was still higher in the FP-EVT group. In conclusion, patients undergoing EVT for AI and FP lesions in contemporary settings were differently characterized by baseline factors. Although the worse clinical outcomes in the FP-EVT group were mainly driven by the higher prevalence of CLTI, the MALE risk was still increased in patients without CLTI.<\/jats:p>\n          <jats:p>\n            <jats:bold>Graphical abstract<\/jats:bold>\n          <\/jats:p>","DOI":"10.1007\/s12928-025-01143-4","type":"journal-article","created":{"date-parts":[[2025,5,24]],"date-time":"2025-05-24T02:12:55Z","timestamp":1748052775000},"page":"852-859","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Comparable clinical characteristics and outcomes of patients undergoing endovascular treatment for aorto-iliac or femoropopliteal lesions"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3574-0685","authenticated-orcid":false,"given":"Yuichi","family":"Saito","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Ohno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayo","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norikiyo","family":"Oka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Takahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sakuramaru","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raita","family":"Uchiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadahiro","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yo","family":"Iwata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Kitahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshio","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,24]]},"reference":[{"key":"1143_CR1","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1016\/S0140-6736(13)61249-0","volume":"382","author":"FG Fowkes","year":"2013","unstructured":"Fowkes FG, Rudan D, Rudan I, Aboyans V, Denenberg JO, McDermott MM, et al. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. Lancet. 2013;382:1329\u201340.","journal-title":"Lancet"},{"key":"1143_CR2","doi-asserted-by":"publisher","first-page":"e1553","DOI":"10.1016\/S2214-109X(23)00355-8","volume":"11","author":"GBD 2019 Peripheral Artery Disease Collaborators","year":"2023","unstructured":"GBD 2019 Peripheral Artery Disease Collaborators. Global burden of peripheral artery disease and its risk factors, 1990\u20132019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Glob Health. 2023;11:e1553\u201365.","journal-title":"Lancet Glob Health"},{"key":"1143_CR3","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.1093\/eurheartj\/ehp355","volume":"30","author":"MJ Alberts","year":"2009","unstructured":"Alberts MJ, Bhatt DL, Mas JL, Ohman EM, Hirsch AT, R\u00f6ther J, et al. Three-year follow-up and event rates in the international reduction of atherothrombosis for continued health registry. Eur Heart J. 2009;30:2318\u201326.","journal-title":"Eur Heart J"},{"key":"1143_CR4","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1136\/heartjnl-2019-316088","volume":"106","author":"SHJ Hageman","year":"2020","unstructured":"Hageman SHJ, de Borst GJ, Dorresteijn JAN, Bots ML, Westerink J, Asselbergs FW, et al. Cardiovascular risk factors and the risk of major adverse limb events in patients with symptomatic cardiovascular disease. Heart. 2020;106:1686\u201392.","journal-title":"Heart"},{"key":"1143_CR5","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1016\/j.jacc.2024.02.013","volume":"83","author":"HL Gornik","year":"2024","unstructured":"Gornik HL, Aronow HD, Goodney PP, Arya S, Brewster LP, Byrd L, et al. 2024 ACC\/AHA\/AACVPR\/APMA\/ABC\/SCAI\/SVM\/SVN\/SVS\/SIR\/VESS Guideline for the Management of Lower Extremity Peripheral Artery Disease: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2024;83:2497\u2013604.","journal-title":"J Am Coll Cardiol"},{"key":"1143_CR6","doi-asserted-by":"publisher","first-page":"3538","DOI":"10.1093\/eurheartj\/ehae179","volume":"45","author":"L Mazzolai","year":"2024","unstructured":"Mazzolai L, Teixido-Tura G, Lanzi S, Boc V, Bossone E, Brodmann M, et al. 2024 ESC Guidelines for the management of peripheral arterial and aortic diseases. Eur Heart J. 2024;45:3538\u2013700.","journal-title":"Eur Heart J"},{"key":"1143_CR7","doi-asserted-by":"publisher","first-page":"e1136","DOI":"10.4244\/EIJ-D-23-01080","volume":"20","author":"Y Gou\u00ebffic","year":"2024","unstructured":"Gou\u00ebffic Y, Brodmann M, Deloose K, Dubosq-Lebaz M, Nordanstig J. Drug-eluting devices for lower limb peripheral arterial disease. EuroIntervention. 2024;20:e1136\u201353.","journal-title":"EuroIntervention"},{"key":"1143_CR8","doi-asserted-by":"publisher","first-page":"1936","DOI":"10.1001\/jama.2015.14851","volume":"314","author":"F Fakhry","year":"2015","unstructured":"Fakhry F, Spronk S, van der Laan L, Wever JJ, Teijink JA, Hoffmann WH, et al. Endovascular revascularization and supervised exercise for peripheral artery disease and intermittent claudication: a randomized clinical trial. JAMA. 2015;314:1936\u201344.","journal-title":"JAMA"},{"key":"1143_CR9","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1093\/eurheartj\/ehac722","volume":"44","author":"D Koeckerling","year":"2023","unstructured":"Koeckerling D, Raguindin PF, Kastrati L, Bernhard S, Barker J, Quiroga Centeno AC, et al. Endovascular revascularization strategies for aortoiliac and femoropopliteal artery disease: a meta-analysis. Eur Heart J. 2023;44:935\u201350.","journal-title":"Eur Heart J"},{"key":"1143_CR10","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.ejvs.2005.09.006","volume":"31","author":"N Diehm","year":"2006","unstructured":"Diehm N, Shang A, Silvestro A, Do DD, Dick F, Schmidli J, et al. Association of cardiovascular risk factors with pattern of lower limb atherosclerosis in 2659 patients undergoing angioplasty. Eur J Vasc Endovasc Surg. 2006;31:59\u201363.","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"1143_CR11","doi-asserted-by":"publisher","first-page":"769","DOI":"10.5551\/jat.52647","volume":"27","author":"T Ko","year":"2020","unstructured":"Ko T, Higashitani M, Uemura Y, Utsunomiya M, Yamaguchi T, Matsui A, et al. Clinical outcome and diverse risk factors for different therapeutic target locations of peripheral artery disease. J Atheroscler Thromb. 2020;27:769\u201379.","journal-title":"J Atheroscler Thromb"},{"key":"1143_CR12","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.ejrad.2010.04.016","volume":"75","author":"JO Balzer","year":"2010","unstructured":"Balzer JO, Thalhammer A, Khan V, Zangos S, Vogl TJ, Lehnert T. Angioplasty of the pelvic and femoral arteries in PAOD: results and review of the literature. Eur J Radiol. 2010;75:48\u201356.","journal-title":"Eur J Radiol"},{"key":"1143_CR13","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s12928-023-00948-5","volume":"39","author":"A Yu","year":"2024","unstructured":"Yu A, Fujimura N, Hayashi M, Harada H. Hybrid treatment of distal bypass and pedal artery angioplasty following intraoperative direct puncture angiography for chronic limb-threatening ischemia with occult vessel. Cardiovasc Interv Ther. 2024;39:91\u20132.","journal-title":"Cardiovasc Interv Ther"},{"key":"1143_CR14","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1007\/s12928-024-00999-2","volume":"39","author":"Y Shima","year":"2024","unstructured":"Shima Y, Taninobu N, Ikuta A, Mushiake K, Tanaka H, Kadota K. Two-year outcomes of endovascular therapy for femoropopliteal arterial lesions for patients with high bleeding risk. Cardiovasc Interv Ther. 2024;39:284\u201392.","journal-title":"Cardiovasc Interv Ther"},{"key":"1143_CR15","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s12928-021-00832-0","volume":"37","author":"H Ando","year":"2020","unstructured":"Ando H, Yamaji K, Kohsaka S, Ishii H, Wada H, Yamada S, et al. Japanese Nationwide PCI (J-PCI) Registry Annual Report 2019: patient demographics and in-hospital outcomes. Cardiovasc Interv Ther. 2020;37:243\u20137.","journal-title":"Cardiovasc Interv Ther"},{"key":"1143_CR16","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1007\/s12928-023-00963-6","volume":"39","author":"T Fujii","year":"2024","unstructured":"Fujii T, Amano K, Kasai S, Kawamura Y, Yoshimachi F, Ikari Y. Impact of renal function on adverse bleeding events associated with dual antiplatelet therapy in patients with acute coronary syndrome. Cardiovasc Interv Ther. 2024;39:28\u201333.","journal-title":"Cardiovasc Interv Ther"},{"key":"1143_CR17","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s12928-023-00920-3","volume":"38","author":"N Nakanishi","year":"2023","unstructured":"Nakanishi N, Kaikita K, Ishii M, Kuyama N, Tabata N, Ito M, et al. Japanese high bleeding risk criteria status predicts low thrombogenicity and bleeding events in patients undergoing percutaneous coronary intervention. Cardiovasc Interv Ther. 2023;38:299\u2013308.","journal-title":"Cardiovasc Interv Ther"},{"key":"1143_CR18","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1161\/CIRCULATIONAHA.117.033502","volume":"137","author":"KA Hicks","year":"2018","unstructured":"Hicks KA, Mahaffey KW, Mehran R, Nissen SE, Wiviott SD, Dunn B, et al. 2017 Cardiovascular and stroke endpoint definitions for clinical trials. Circulation. 2018;137:961\u201372.","journal-title":"Circulation"},{"key":"1143_CR19","doi-asserted-by":"publisher","first-page":"2584","DOI":"10.1016\/j.jcin.2021.08.079","volume":"14","author":"V Lakhter","year":"2021","unstructured":"Lakhter V, Weinberg MD, Galmer A, Mishra S, Dalsania R, Das S, et al. Objective outcome measures for trials in patients with chronic limb-threatening ischemia across 2 decades: analysis and recommendations. JACC Cardiovasc Interv. 2021;14:2584\u201397.","journal-title":"JACC Cardiovasc Interv"},{"key":"1143_CR20","doi-asserted-by":"publisher","first-page":"2736","DOI":"10.1161\/CIRCULATIONAHA.110.009449","volume":"123","author":"R Mehran","year":"2011","unstructured":"Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J, et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation. 2011;123:2736\u201347.","journal-title":"Circulation"},{"key":"1143_CR21","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.jcin.2023.11.040","volume":"17","author":"J Li","year":"2024","unstructured":"Li J, Varcoe R, Manzi M, Kum S, Iida O, Schmidt A, et al. Below-the-knee endovascular revascularization: a position statement. JACC Cardiovasc Interv. 2024;17:589\u2013607.","journal-title":"JACC Cardiovasc Interv"},{"key":"1143_CR22","doi-asserted-by":"publisher","first-page":"2697","DOI":"10.1253\/circj.CJ-12-0492","volume":"76","author":"Y Soga","year":"2012","unstructured":"Soga Y, Iida O, Kawasaki D, Yamauchi Y, Suzuki K, Hirano K, et al. Contemporary outcomes after endovascular treatment for aorto-iliac artery disease. Circ J. 2012;76:2697\u2013704.","journal-title":"Circ J"},{"key":"1143_CR23","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1093\/eurheartj\/ehx095","volume":"39","author":"V Aboyans","year":"2018","unstructured":"Aboyans V, Ricco JB, Bartelink MEL, Bj\u00f6rck M, Brodmann M, Cohnert T, et al. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries. Endorsed by: the European Stroke Organization (ESO)The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). Eur Heart J. 2018;39:763\u2013816.","journal-title":"Eur Heart J"},{"key":"1143_CR24","doi-asserted-by":"publisher","first-page":"e1154","DOI":"10.4244\/EIJ-D-24-00037","volume":"20","author":"YH Yoon","year":"2024","unstructured":"Yoon YH, Lee JH, Hwang WM, Park HW, Roh JH, Lee SJ, et al. Treatment extent of femoropopliteal disease and clinical outcomes following endovascular therapy. EuroIntervention. 2024;20:e1154\u201362.","journal-title":"EuroIntervention"},{"key":"1143_CR25","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.4244\/EIJ-D-21-00192","volume":"17","author":"T Asano","year":"2022","unstructured":"Asano T, Ono M, Dai Z, Saito A, Kanie T, Takaoka Y, et al. Temporal trends in clinical outcomes after percutaneous coronary intervention: a systematic review of 66,327 patients from 25 all-comers trials. EuroIntervention. 2022;17:1318\u201329.","journal-title":"EuroIntervention"}],"container-title":["Cardiovascular Intervention and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12928-025-01143-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12928-025-01143-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12928-025-01143-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T16:39:41Z","timestamp":1757695181000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12928-025-01143-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,24]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["1143"],"URL":"https:\/\/doi.org\/10.1007\/s12928-025-01143-4","relation":{},"ISSN":["1868-4300","1868-4297"],"issn-type":[{"value":"1868-4300","type":"print"},{"value":"1868-4297","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,24]]},"assertion":[{"value":"17 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}